Terry L Bowersock

US Patent:

6656470, Dec 2, 2003

Filed:

May 11, 2001

Appl. No.:

09/853919

Inventors:

Terry L. Bowersock - Portage MI
Paul Guimond - Kalamazoo MI
Tzu-Chi R. Ju - Thousand Oaks CA
Argaw Kidane - Greensboro NC

Assignee:

Pharmacia Upjohn Company - Kalamazoo MI

International Classification:

A61K 914

US Classification:

4241841, 424489, 424490, 424493, 424499

Abstract:

The invention provides a vaccine composition and a method of preparation including the steps of: forming a water-in-oil emulsion including an alginate in water, an oil, an antigen, and either (a) a cellulose ether and at least one nonionic surfactant or (b) a PEO-PPO-PEO triblock copolymer surfactant and at least one nonionic surfactant; followed by crosslinking the alginate in the emulsion with at least two cations selected from the group consisting of aluminum, barium, calcium, lithium, manganese, strontium, and zinc, to form antigen-containing, crosslinked alginate microparticles; and harvesting the microparticles. Another aspect of the invention is a method of vaccinating a vertebrate species including the step of administering to the species a vaccine composition prepared according to the method of the invention. The compositions of the invention have improved antigen loading, reduced microparticle size, increased hydrophobicity, improved uptake by antigen sampling cells, controlled antigen release characteristics, and improved immunogenicity.

US Patent:

7160544, Jan 9, 2007

Filed:

Nov 10, 2003

Appl. No.:

10/705660

Inventors:

Terry L. Bowersock - Portage MI, US
Paul Guimond - Kalamazoo MI, US
Tzu-Chi R. Ju - Thousand Oaks CA, US
Argaw Kidane - Greensboro NC, US

Assignee:

Pharmacia & Upjohn Company - Kalamazoo MI

International Classification:

A61K 9/14

US Classification:

4241841, 4241851, 4242771

Abstract:

The invention provides a vaccine composition and a method of preparation including the steps of: forming a water-in-oil emulsion including an alginate in water, an oil, an antigen, and either (a) a cellulose ether and at least one nonionic surfactant or (b) a PEO-PPO-PEO triblock copolymer surfactant and at least one nonionic surfactant; followed by crosslinking the alginate in the emulsion with at least two cations selected from the group consisting of aluminum, barium, calcium, lithium, manganese, strontium, and zinc, to form antigen-containing, crosslinked alginate microparticles; and harvesting the microparticles. Another aspect of the invention is a method of vaccinating a vertebrate species including the step of administering to the species a vaccine composition prepared according to the method of the invention. The compositions of the invention have improved antigen loading, reduced microparticle size, increased hydrophobicity, improved uptake by antigen sampling cells, controlled antigen release characteristics, and improved immunogenicity.

US Patent:

56744951, Oct 7, 1997

Filed:

Feb 27, 1995

Appl. No.:

8/394802

Inventors:

Terry L. Bowersock - West Lafayette IN
Kinam Park - West Lafayette IN
Robert E. Porter - West Lafayette IN

Assignee:

Purdue Research Foundation - West Lafayette IN

International Classification:

A61K 3900
A61K 4500
A61K 3902
A61F 1300

US Classification:

4241841

Abstract:

A vaccine composition including an antigen dispersed in an alginate gel is described. The alginate gel is preferably in the form of discrete particles coated with a polymer. Vaccination of vertebrate species can be accomplished by administering the alginate-based vaccine compositions orally.

US Patent:

53524489, Oct 4, 1994

Filed:

Jul 20, 1992

Appl. No.:

7/916533

Inventors:

Terry L. Bowersock - Lafayette IN
Waleed S. W. Shalaby - Mt. Pleasant SC
William E. Blevins - Offerbem IN
Michel Levy - West Lafayette IN
Kinam Park - West Lafayette IN

Assignee:

Purdue Research Foundatioin - West Lafayette IN

International Classification:

A61K 3900
A61K 4734
A61K 916
A61K 922

US Classification:

424438

Abstract:

An oral vaccine formulation is provided for stimulation of an immune response in gut-associated lymphoid tissues. The formulation comprises an enzymatically degradable antigen in a hydrogel matrix. In ruminant species, the vaccine formulation, upon oral administration, is formed to pass through the rumen without substantial hydration and then into the post-ruminal portion of the digestive tract where the antigen is released for contact with the gut-associated lymphoid tissue.